Christman

Ventrix is a clinical-stage biotechnology company focused on developing a new class of pro-regenerative biotherapeutics for cardiac repair. The company's lead product, VentriGel, is an injectable extracellular matrix (ECM) hydrogel derived from porcine cardiac tissue designed to provide a scaffold for healthy cell migration and tissue repair following a heart attack. By mimicking the natural environment of the heart, Ventrix's technology aims to reduce scar tissue formation and improve cardiac function in patients with heart failure. The company was co-founded by Dr. Karen Christman, a pioneer in biomaterials and regenerative medicine at UC San Diego.